AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Mereo BioPharma Group plc investigated for securities fraud and unlawful practices.
ByAinvest
Sunday, Aug 17, 2025 11:49 am ET1min read
Pomerantz LLP is investigating claims on behalf of Mereo BioPharma Group plc investors. The investigation concerns whether the company and its officers have engaged in securities fraud or unlawful business practices. Mereo and Ultragenyx Pharmaceutical Inc. announced the Phase 3 portion of the Orbit study for UX143 in pediatric and young adult patients with osteogenesis imperfecta is progressing toward a final analysis around the end of the year.
Pomerantz LLP, a leading firm in corporate, securities, and antitrust class litigation, has initiated an investigation into claims on behalf of investors of Mereo BioPharma Group plc (NASDAQ: MREO). The investigation focuses on whether the company and its officers or directors have engaged in securities fraud or other unlawful business practices [1].The investigation was prompted by a press release issued by Mereo and its development partner Ultragenyx Pharmaceutical Inc. on July 9, 2025. The announcement stated that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) is progressing toward a final analysis, expected around the end of the year [2]. Following this news, Mereo's American Depositary Receipt (ADR) price fell by $1.25 per share, or 42.52%, to close at $1.69 per share on July 10, 2025 [2].
Mereo BioPharma Group plc is a biopharmaceutical company that develops medicines for rare diseases and cancer. The company is working on treatments like setrusumab for brittle bone disease and alvelestat for severe lung disease [4]. Despite the potential of the company's pipeline, recent market reactions suggest investor concerns about the company's practices and the progress of its clinical trials.
Investors are advised to contact Danielle Peyton at Pomerantz LLP for more information or to join the class action. The contact details are 646-581-9980, ext. 7980 [1, 2, 3].
References:
[1] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-biopharma-group-plc---mreo-302521606.html
[2] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo-biopharma-group-plc---mreo-302525782.html
[3] https://www.bakersfield.com/ap/news/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-mereo/article_147bd3c8-62b9-5682-88e8-6c9e475da3aa.html
[4] https://finance.yahoo.com/news/mereo-biopharma-group-mreo-announced-134505525.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet